STAT+: FDA advisory panel meetings became ‘rarer and tougher’ in 2020

Among the myriad changes wrought by the Covid-19 pandemic, Food and Drug Administration advisory committee meetings to review medicines are “rarer and tougher” now, according to one Wall Street analyst.

Over the past year, just half of new drug applications taken to advisory committees were recommended for regulatory approval. That compares with 78% in 2019 and a rate of more than 80% in three of the four years before that, according to Cowen analyst Rick Weissenstein, who cited an analysis by the Prevision Policy consulting firm in an investor note.

Continue to STAT+ to read the full story…

Read Original Article: STAT+: FDA advisory panel meetings became ‘rarer and tougher’ in 2020 »